Prorenin periconceptionally and in pregnancy: Does it have a physiological role?

Rosalieke E. Wiegel a, Frauke von Versen-Höynck b, Régine P.M. Steegers-Theunissen a, Eric A. P. Steegers a, A.H. Jan Danser c, A.H. Jan Danser e

a Department of Obstetrics and Gynecology, Erasmus MC, Rotterdam, the Netherlands
b Hannover Medical School, Department of Obstetrics and Gynecology, Hannover, Germany
c Department of Internal Medicine, Erasmus MC, Rotterdam, the Netherlands

c a.danser@erasmusmc.nl (A.H.J. Danser).

1. Introduction

Successful conception and the subsequent physiologic adaptation to pregnancy involves the complex coordination of different organ systems, including the endocrine, cardiovascular and renal systems, to ensure the well-being of the mother and the fetus during pregnancy. These changes start in the luteal phase of the menstrual cycle and peak at the end of the first trimester prior to the increase in metabolic demands of mother and fetus and in anticipation of growing needs in the second half of pregnancy (Fig. 1). Systemic vasodilation occurs as early as 3 weeks post-conception (5 weeks gestation) (Chapman et al., 1998), and is accompanied by a decrease in peripheral vascular resistance, reaching a nadir during the mid-second trimester. A first reduction in maternal systolic, diastolic and mean arterial blood pressure is observed at a median of 6 weeks gestation, with a return to non-pregnant levels during the last month of pregnancy (Mahendru et al., 2012; Chapman et al., 1998; Robson et al., 1989; Capeless and Clapp, 1989; Robb et al., 2009). Heart rate increases in early pregnancy, while cardiac output and left atrial dimension increase from preconception to mid-gestation, with a decline after 32–35 weeks of gestation. Carotid femoral pulse wave velocity and augmentation index decline continuously from baseline preconception levels. Reductions in renal afferent and efferent arteriolar resistance result in rises in renal plasma flow, ([RPF], by 50–80%) and glomerular filtration rate ([GFR], by 40–65%) (Sims and Krantz, 1958; De Alvarez, 1958; Assali et al., 1959; Roberts et al., 1996; Dunlop, 1981). This will increase creatinine and urea clearances, thereby lowering their plasma level (Roberts et al., 1996; Sims and Krantz, 1958; Kuhlback and Widholm, 1966; Nice, 1935).

The renin-angiotensin-aldosterone system (RAAS) is a key player in this adaptation process. Renin cleaves angiotensin (Ang) I from angiotensinogen, which is subsequently converted by ACE into Ang II, a potent vasoconstrictor and growth factor which also stimulates the synthesis of aldosterone. Increases in Ang II and aldosterone levels are necessary to achieve the 30–40% increase in intravascular volume that is required in normal pregnancy to allow the above-described changes. Increases in Ang II particularly depend on increases in renin and angiotensinogen, and to a lesser degree on increases in angiotensin-converting enzyme (ACE) (Danser et al., 1998, 2007). Remarkably, the levels of renin’s precursor, prorenin, also increase substantially in pregnant women. This is unexpected, since prorenin is inactive (due to the fact

* Corresponding author. Erasmus MC, University Medical Center Rotterdam, Department of Internal Medicine, Division of Pharmacology and Vascular Medicine, Room EE1418b Wytemaweg 80, 3015CN, Rotterdam, the Netherlands.
E-mail address: a.danser@erasmusmc.nl (A.H.J. Danser).

https://doi.org/10.1016/j.mce.2020.111118
Received 27 May 2020; Received in revised form 24 November 2020; Accepted 6 December 2020
Available online 17 December 2020
0303-7207/© 2020 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
that a so-called prosegment covers its active site; Fig. 2), raising the question why prorenin would rise at all. Normally under conditions where the RAAS is activated, e.g. in heart failure and patients with renal artery stenosis, it is renin rather than prorenin which rises (Danser et al., 1997; Klotz et al., 2009). Indeed, particularly during additional blockade of the RAAS with RAAS inhibitors, renin rises may be > 100-fold (Balcarek et al., 2014; Klotz et al., 2009). To display activity, prorenin needs to be converted to renin. This proteolytic process involves the cleavage of the prosegment by an as yet unknown enzyme, and is limited to the kidney. Of interest, under physiological conditions (pH 7.4, 37 °C), a small fraction of prorenin (∼1% or less) occurs in a so-called ‘open’ conformation, i.e., a conformation where the prosegment has moved out of the enzymatic cleft (Schalekamp et al., 2008) (Fig. 2). Hence, it no longer covers the cleft, and thus such prorenin is able to display enzymatic activity to the same degree as renin, although its prosegment is still present (Schalekamp et al., 2008). Theoretically, particularly under conditions where prorenin levels are high (like in pregnancy) this ‘non-proteolytic’ activation of prorenin could contribute to Ang I generation in blood. Studies in transgenic animals with excessively high prorenin levels (Campbell et al., 2009) support this view, but in-vivo data in humans confirming this phenomenon are lacking. A further possibility, actively studied over the last 20 years, is that prorenin binds to a receptor, which then facilitates non-proteolytic activation. According to this theory, prorenin might contribute to angiotensin generation at any non-renal tissue site simply by binding to its receptor, without the need for a prosegment-cleaving enzyme. This is a very attractive theory, particularly because humans have relatively high prorenin levels which increase even further due to unknown reasons in conditions like pregnancy and diabetes. The presence of a receptor would finally explain why prorenin exists at all. A putative candidate was proposed nearly 20 years ago, the so-called (pro)renin receptor (Nguyen et al., 2002). It not only allowed prorenin to display Ang I-generating activity, but also to act as an angiotensin-independent agonist. However, prorenin-(pro)renin receptor interaction required prorenin levels in the nanomolar range (Batenburg et al., 2011), i.e. many orders of magnitude above its normal levels, even under conditions where its levels have increased (like in pregnancy). Thus, such interaction is highly unlikely to ever occur in vivo (except in transgenic animals), and more recent studies suggest that the (pro)renin receptor rather exerts RAAS-independent functions (Lu et al., 2016; Ren et al., 2018).

This paper describes the source(s) of prorenin during the periconception period and in pregnancy, and discusses its regulators and potential role(s), among others focusing on preeclampsia, where elegant transgenic models have yielded novel insights. It ends with discussing the long-term consequences of inappropriate RAAS activity in

Fig. 1. Adaptation of endocrine, cardiovascular and renal parameters from preconceptional baseline throughout pregnancy and postpartum. AI, augmentation index; AU, arbitrary units; CO, cardiac output; GFR, glomerular filtration rate; hCG, human chorionic gonadotropin; MAP, mean arterial pressure; RPF, renal plasma flow; SVR, systemic vascular resistance.

Fig. 2. Renin and prorenin conformations. Under physiological conditions (pH 7.4, 37 °C), a small fraction of prorenin (∼1% or less) occurs in the so-called ‘open’ conformation, i.e., a conformation where the prosegment has moved out of the enzymatic cleft, thus allowing it to react with angiotensinogen to yield angiotensin I. Yet, the majority of prorenin is closed and inactive. Cleavage of the prosegment (also known as ‘proteolytic’ activation) occurs exclusively in the kidney, and depends on an as yet unidentified enzyme.
pregnancy, and offers directions for future research.

2. Circulating renin-angiotensin-aldosterone system in pregnancy: source(s) of prorenin

Circulating angiotensinogen levels increase 3-5-fold in pregnant women (Verdonk et al., 2015). This is due to estrogen-stimulated upregulation of hepatic angiotensinogen synthesis (Klett et al., 1992; Uijl et al., 2019). The rise in angiotensinogen is accompanied by a modest (>1.5-2-fold) rise in the concentration of plasma renin, either due to the decrease in blood pressure (affecting renal afferent/effferent arteriolar tone and renal JG cell responsiveness) or the fact that progesterone acts as an antagonist towards the mineralocorticoid receptor (Landau and Lugibihl, 1958). Together, the upregulation in plasma renin concentration and angiotensinogen result in a 2-3-fold rise in plasma renin activity (PRA), thereby raising Ang I and II levels throughout pregnancy. Remarkably, the Ang II elevation does not result in a rise in blood pressure. In fact, the constrictor sensitivity to exogenous Ang II is diminished in pregnancy. This could relate to a downregulation of constrictor Ang II type 1 (AT₁) receptors, an upregulation of dilator Ang II type 2 (AT₂) receptors, and/or the upregulation of counterbalancing dilator mechanisms including nitric oxide (NO), prostaglandins and the Ang-(1–7)/Mas receptor axis (Mishra et al., 2019; Gant et al., 1980; Verdonk et al., 2014; South et al., 2019). Renin levels fall within 24 h after delivery, thus allowing a rapid post-pregnancy normalization of circulating Ang II and aldosterone (Derkx et al., 1987). Angiotensinogen levels fall less rapidly, possibly due to puerperal activity of the corpus luteum, resulting in continued estrogen release after birth (Wier et al., 1975; Weiss and Rifkin, 1975; Conrad et al., 2019a).

Prorenin levels increase 4-5-fold by week 8, and drop only slowly after delivery over a period of several days (Sealey et al., 1985; Derkx et al., 1987). The latter contrasts with the rapid decrease of renin after pregnancy, and is suggestive for an extrarenal source of prorenin with continued activity after birth. The much higher rise in prorenin rapidly after conception and during pregnancy (versus renin) also supports an extrarenal source. Studies in pregnancies lacking a corpus luteum (Fig. 3) have revealed that the corpus luteum is the major contributor to this rise in circulating prorenin, as well as its continued synthesis after birth. Indeed, no such increase in circulating prorenin was seen in pregnancies without a corpus luteum (Derkx et al., 1987). In such pregnancies, the prorenin rise was as modest as the rise in renin, and prorenin decreased in parallel with renin after parturition (Sealey et al., 1985; Derkx et al., 1987). Recent data obtained in 277 women with either no corpus luteum, 1 corpus luteum or >1 corpus luteum further confirmed the direct relationship between corpus luteum number and prorenin levels (Wiegel et al., 2020). Taken together, these data indicate that renin upregulation in pregnancy is kidney-driven, while the ovaries are the main source of prorenin levels in pregnant women.

Chorionic and amniotic fluid contain prorenin levels that are many orders of magnitude above those in blood. Early in pregnancy the chorionic cavity is larger, while it disappears after 8 weeks, when human chorionic gonadotropin (hCG) levels decline and the amniotic cavity becomes predominant (Iksikovitz et al., 1992). The amniotic tissue does not synthesize prorenin, and it is believed that chorionic prorenin passes through the amnion into the amniotic fluid. Since the amniotic fluid levels of prorenin were normal in pregnancies without a corpus luteum (Derkx et al., 1987), it appears that chorionic prorenin does not contribute to the levels of prorenin in plasma. Other potential sources of circulating prorenin are the uterus and placenta. Indeed, making use of the isolated perfused cotyledon setup, Lenz et al. were able to demonstrate prorenin release to the maternal but not the fetal circulation (Lenz et al., 1991). Direct evidence for decidual prorenin release into the circulation is not available. Yet, it may contribute to gestational fluid prorenin (Shaw et al., 1989). Moreover, Brar et al. demonstrated prorenin release from the uteroplacental unit in pregnant women (Brar et al., 1986). This conclusion was based on the presence of higher prorenin levels in uterine venous blood versus arterial blood. No such differences were observed for renin. In summary, next to the ovary and kidneys, a third (and probably modest) source of circulating prorenin in pregnancy is the uteroplacental unit. Lenz et al. estimated that <5% of circulating prorenin in pregnancy originates from the placenta (Lenz et al., 1991). The very modest rises in prorenin in a woman without a corpus luteum, also at late term (Derkx et al., 1987), is in agreement with this view.

Prorenin levels in blood normally are around 10 times higher than those of renin (Danser et al., 1998). In pregnancy, with renin increasing <2-fold, and prorenin increasing 4-5-fold, this results in renin levels representing <5% of total renin (=renin + prorenin). Under such conditions, a small fraction of prorenin displaying activity (Fig. 2) might

---

Fig. 3. Physiological follicle development followed by spontaneous conception with one corpus luteum compared to pregnancies achieved through assisted reproduction with fresh embryo transfer (ET) after superovulation with multiple corpora lutea or frozen ET in a natural cycle with one corpus luteum or frozen ET in a programmed cycle after suppression of the pituitary-ovarian axis in the absence of a corpus luteum.
contribute to Ang I generation in blood to the same degree as renin. Initial studies linked prorenin to vasodilation, albeit via an unknown mechanism (Sealey et al., 1991, 1996). Direct prorenin-induced effects (e.g., independent of Ang II formation) may involve a receptor, and although the (pro)renin receptor has been suggested to be this receptor (Pringle et al., 2015), convincing evidence that it plays such a role in vivo is lacking (Batenburg et al., 2011).

3. Corpus luteum, early gestational hemodynamic adaptation and circulating prorenin

In conceptions lacking a corpus luteum the systemic and renal adaptations in the first weeks of pregnancy are attenuated. This is suggestive for a critical role of corpus luteum factors in the maternal hemodynamic adaptation in early gestation (von Versen-Hoynck et al., 2019; Conrad et al., 2019b). Indeed, the corpus luteum is considered a ‘functional ovarian cyst’ during early pregnancy, i.e., before the luteal-placental shift, when placental hormones (synthesized by syncytiotrophoblast cells) become of greater importance. Moreover, prospective cohort studies in infertile populations showed that the risk to develop preeclampsia is doubled in women who lack a corpus luteum (von Versen-Hoynck et al., 2019; Giström Ernstad et al., 2019). The corpus luteum evolves from remnant tissue of the ovulated follicle with the preovulatory surge of luteinizing hormone (LH) from the pituitary gland as the main stimulus. It has significant steroidogenic and angiogenic activity in both the luteal phase of a menstrual cycle and in early pregnancy (Devoto et al., 2009). Transformation of the follicle into the corpus luteum involves vascular endothelial cells undergoing intense proliferation and the formation of a rich vascular network, essential for the delivery of substrates.

A physiological pregnancy is preceded by one corpus luteum. In contrast, pregnancies achieved via ovulation stimulation treatment often begin in a non-physiological endocrine milieu due to suppression of the pituitary-ovarian axis and the absence of the corpus luteum or due to superovulation with the presence of more than one corpus luteum (Fig. 3). Corpus luteum function is controlled by the interaction of several hormones secreted by the pituitary gland, and in case of pregnancy, by the decidua and the placenta. It contains steroidogenic cells (theca-lutein [small luteal cells] and granulosa-lutein cells [large luteal cells]) and non-steroidogenic cells (endothelial cells, pericytes, fibroblasts and immune cells) (Davis and Rueda, 2002; Alila and Hansel, 1984). The corpus luteum synthesizes hormones, growth factors, angiogenic factors and vasoactive substances to establish and maintain pregnancy. These include 17β-estradiol, progesterone, proestradilans, relaxin, oxytocin, vasopressin, inhibin, vascular endothelial growth factor, endothelin-1 (ET-1), and prorenin (Ebisch et al., 2008; Kämper et al., 2014). In the absence of pregnancy, the corpus luteum will cease synthesis and the structure will regress in size over time (Rowan et al., 2008).

Given the suboptimal maternal hemodynamic adaptation in pregnancies lacking a corpus luteum, it is likely that this insufficient adaptation relies at least on one or more of the factors released by the corpus luteum into the circulation. Prorenin is produced by the mature ovarian follicle and the corpus luteum in response to gonadotropic stimulation (Derks et al., 1987). Its levels directly relate to the number of ovarian follicles, with a modifying role for the hormones applied in the in-vitro fertilization (IVF) protocol (Itskovitz and Sealey, 1987; Itskovitz et al., 1987; Wiegel et al., 2020). The former also applies to relaxin, which, unlike prorenin, is exclusively produced by the corpus luteum (Weiss et al., 1993; Mushayandebvu et al., 1998; Arthur et al., 1996; Hanting et al., 1996; Giström Ernstad et al., 2019). In other words, relaxin is entirely absent in pregnancies lacking a corpus luteum. Relaxin causes relaxation via NO and prostacyclin, and thus potentially contributes to the systemic and renal vasodilation and the increase in GFR in early pregnancy. Indeed, the absence of relaxin associated with a diminished increase in GFR and higher serum sodium and creatinine levels. Moreover, lower relaxin levels ultimately promote preeclampsia (Conrad and Davison, 2014; Post Uiterweer et al., 2020). Relaxin also stimulates prorenin production (Poisner et al., 1990). Finally, estrogens promote vasodilation via NO and prostacyclin, by stimulating endothelial NO synthase (eNOS) and cyclooxygenase-1, respectively. This increases blood flow, particularly in the uterine vascular bed. The latter likely involves 17β-estradiol-induced upregulation of dilator AT2 receptors (Mishra et al., 2019). As discussed, estrogen additionally upregulates angiotensinogen, allowing an increase in Ang II levels. Simultaneously, estrogens stimulate 11β-hydroxysteroid dehydrogenase 2, thereby preventing glucocorticoids from increasing blood pressure via binding to mineralocorticoid receptors (Baggio et al., 1990). Progesterone, like 17β-estradiol, promotes vasodilation via eNOS and cyclooxygenase-1 (Simoncini et al., 2007; Hermenegilde et al., 2005), and is thus able to antagonize Ang II-induced vasoconstriction (Nakamura et al., 1988). Summarizing, the corpus luteum secretes multiple factors that, through modulation of circulating RAAS activity, affect maternal hemodynamic adaptation to pregnancy (Fig. 4). Yet, why it secretes prorenin in large amounts cannot be deduced from the above findings. A further possibility is that prorenin exerts effects locally, in the ovaries, uterus and/or placenta.

4. Prorenin synthesis in the ovaries, uterus and placenta: does it have a local function?

Extrarenal cells that synthesize prorenin during pregnancy include theca cells, chorionic cells, decidual cells and placental cytotrophoblasts. Prorenin, in contrast to renin, is not stored in vesicles, and thus its local synthesis is likely to result in direct release, yielding high prorenin levels in the immediate surrounding of prorenin-synthesizing cells, i.e., in follicular, chorionic, and amniotic fluid. Indeed, chorionic prorenin levels were the highest ever measured in the human body: they amounted to 1000 times the normal prorenin levels in the circulation (Itskovitz et al., 1992). At such high levels, given that up to 1% of prorenin occurs in the open (active) conformation (Schalekamp et al., 2008), Ang I generation is likely to take place even in the absence of any prorenin-renin conversion. In fact, assuming that sufficient angiotensinogen is available, the degree of Ang I generation under such conditions might be 100 times above the normal PRA. This implies that this prorenin, at least locally, is capable of promoting Ang II-mediated effects.

4.1. Ovaries

Prorenin levels in follicular fluid are approximately 10-fold higher than those in plasma, both in normal and stimulated menstrual cycles (Fernandez et al., 1985; Glorioso et al., 1986). Theca cells of the follicle and the luteinized thecal cells of the corpus luteum after ovulation are the source of this prorenin. Prorenin synthesis occurs in response to the gonadotropic hormones LH and hCG, and involves the adenyl cyclase-cyclic adenosine monophosphate (cAMP) pathway (Sealey et al., 1985; Itskovitz et al., 1987; Brunswig-Spickenheier and Mukhopadhyay, 2003; Do et al., 1988). Activation of protein kinase C (PKC), e.g., by tumor necrosis factor (TNF)-α, inhibits this process (Brunswig-Spickenheier and Mukhopadhyay, 1993). High follicular prorenin levels correlate with atresia (characterized by high testosterone levels and a low estradiol/progesterone ratio, together resulting in granulosa cell degeneration), while low follicular prorenin levels associate with immature follicles (Itskovitz et al., 1991). In other words, follicular prorenin levels should be in an ideal range, and not be too low or too high. Possibly, this is related to the need for ‘optimal’ Ang II levels. Multiple effects of Ang II in the ovaries have been described, ranging from stimulation of steroidogenesis to oocyte maturation, ovulation and atresia (Itskovitz et al., 1991; Cornwellis et al., 1990; Yoshimura et al., 1992; Peterson et al., 1993; Pellicer et al., 1988; Morris and Paulson, 1993; Paulson et al., 1989; McNatty et al., 1979; Seibel et al., 1989; Lightman et al., 1987). Ang II might also display vascular effects in the
follicular microcirculation (affecting blood flow) and facilitate the process of neovascularization that is required for appropriate corpus luteum formation (Fernandez et al., 1985; Stirling et al., 1990). Many of these Ang II effects are controversial (Naftolin et al., 1989; Yoshimura, 1997). Both AT$_1$ and AT$_2$ receptor stimulation have been implied, with the AT$_2$ receptor being the predominant Ang II receptor in the ovaries (Yoshimura et al., 1996). Here it is of interest to note that AT$_2$ receptor stimulation requires higher Ang II levels than AT$_1$ receptor stimulation.

![Fig. 4.](image-url)

The corpus luteum secretes multiple factors that directly or indirectly modulate circulating RAAS activity and affect maternal hemodynamic adaptation during early human pregnancy. Progesterone acts as a mineralocorticoid receptor antagonist, thus blocking the effects of aldosterone. Ang, angiotensin; AT$_1$R, angiotensin II type 1 receptor and AT$_2$R, angiotensin II type 2 receptor; GFR, glomerular filtration rate; MAP, mean arterial pressure; Na$^+$, sodium; NO, nitric oxide; RPF, renal plasma flow.

![Fig. 5.](image-url)

Local prorenin synthesis in the ovaries, uteroplacental unit and fetal membranes, known stimulators and inhibitors of prorenin synthesis, and possible functions (local and systemic) of prorenin. ATP, adenosine triphosphate; Ca$^{2+}$, extracellular calcium; cAMP, cyclic adenosine monophosphate; hCG, human chorionic gonadotropin; PDE, phosphodiesterase; PDEi, phosphodiesterase inhibitor; PKC, protein kinase C; TNF, tumor necrosis factor; VEGF, vascular endothelial growth factor.
4.2. Uteroplacental unit

The decidual, the maternal bed of the placenta, originates from differentiating endometrial stroma cells. This ‘decidualization’ process (involving cell growth, proliferation and angiogenesis) is primarily coordinated by ovarian steroids (Shah et al., 1991). It occurs during the secretory phase of the endometrial cycle, to prepare the receptive endometrium for implantation, and is maintained during pregnancy. Both the endometrium and decidua release prorenin, although quantitatively the decidual contribution is most important (Shaw et al., 1989). Most groups investigating prorenin release from decidua cells additionally find ‘renin’ activity, i.e., Ang I-generating activity even without converting prorenin to renin. Yet, in reality this represents the fact that, as discussed, a small fraction of prorenin occurs in the open conformation (Fig. 5) (Martini et al., 2017). Martini et al. investigated whether decidual cells possibly release prorenin in the ‘open’ conformation, based on the concept that the low pH conditions under which its synthesis and release occur favor the open conformation (Schalekamp et al., 2008). If so, prorenin would display local activity, in the immediate surrounding of its release, before returning to its closed, inactive conformation at greater distance from its release site. Unfortunately, no evidence for this concept could be obtained. Among the stimulators of decidual prorenin synthesis are progesterone (Shah et al., 1991) and relaxin (Poisner et al., 1990). Remarkably, ET-1, known to suppress renin synthesis in the kidney (Verdonk et al., 2015), actually stimulated decidual prorenin production (Poisner et al., 1990; Chao et al., 1993), while TNF-α, interleukin-1β and interferon-γ inhibited it (Poisner et al., 1991; Jikihara et al., 1995, 1996). Like in theca cells, the adenylyl cyclase–cAMP pathway is the intracellular mediator of this process, with modulatory roles for PKC and calcium (Poisner et al., 1991; Chao et al., 1994). Decidual prorenin production has been linked to vascular endothelial growth factor expression through local RAAS activation (Lumbers et al., 2015). Since vascular endothelial growth factor is a well-known contributor to de novo vessel formation, prorenin may thus facilitate decidualization. Interestingly, altered endometrial AT₁ and AT₂ receptor expression has been suggested to underlie recurrent miscarriage (Qi et al., 2020).

The placental cells that synthesize prorenin are the cytrophoblasts (Poisner et al., 1994). Cytotrophoblasts decrease in number during gestation, when they fuse to syncytiotrophoblasts. As a consequence, placental prorenin levels are low at term, and hence prorenin release into the maternal circulation at the end of pregnancy will be similarly low. Stimulators of placentral prorenin production are hCG and β-adrenergic receptor agonists (Downing et al., 1994). This involves the adenylyl cyclase–cAMP pathway (Poisner et al., 1994; Downing et al., 1994). Phosphodiesterase inhibitors (blocking cAMP degradation) further upregulate prorenin release (Poisner et al., 1994; Downing et al., 1996), while Ang II and TNF-α block it (Poisner, 1995).

The fetal membranes, chorion and the amnion, originate from the outer trophoblast layer of the implanting blastocysts. Only chorionic cells (cytotrophoblasts) synthesize and release prorenin (Plinet et al., 1988; Duncan et al., 1990). Prorenin is capable of passing through the amnion, thus explaining why amniotic fluid contains high prorenin levels, despite the fact that amniotic cells do not synthesize prorenin (Acker et al., 1982; Itskovitz et al., 1992). A potential candidate facilitating prorenin passage is megalin (Sun et al., 2020). Megalin is a 600 kDa endocytic receptor, highly expressed in placental syncytiotrophoblasts, which is thought to contribute to transport functions (Akour et al., 2013). Decidual cells are an unlikely source of prorenin in the gestational sac, given the fact that the gestational prorenin levels were normal in tubal pregnancy, when decidualization is absent (Itskovitz et al., 1992). Chorionic prorenin synthesis depends on cAMP, PKC and extracellular calcium (Duncan et al., 1990). To what degree the high prorenin levels in chorionic and amniotic fluid play a role beyond Ang II formation remains a matter of debate. Possible roles of Ang II concern its effects on angiogenesis, growth and vascular constriction/dilation (the latter mediated via vasodilator prostanooids) (Fernandez et al., 1985; Glance et al., 1985; Magnes et al., 1992; Anton et al., 2008; Pringle et al., 2011; Franklin et al., 1974).

5. Prorenin and preeclampsia: lessons from animal models

The hemodynamic adaptation process in pregnancy, i.e. the expansion of plasma volume and the decrease in vascular resistance, is less pronounced in preeclampsia (Spaanderman et al., 2001). Pregnancies complicated by preeclampsia are characterized by diminished uteroplacental flow (Schuchter et al., 2001), suggesting that the normally occurring expansion of plasma volume and increase in cardiac output are essential for the maintenance of a sufficient uteroplacental flow. Remarkably, despite this reduction in circulating volume, renin and angiotensinogen are downregulated in preeclampsia compared with normal pregnancy (Verdonk et al., 2015). Whether this is a physiological response to the increased blood pressure or an active contributor to the pathophysiology of preeclampsia is unknown. Circulating prorenin levels in preeclampsia are in the normal range (Nicholson et al., 1987; Verdonk et al., 2015; Brar et al., 1987), although data during early pregnancy in this condition are lacking. Thus, we do not know whether the follicular/corpus luteum release of prorenin in early pregnancy is altered in women who develop preeclampsia. Data on prorenin levels in the uteroplacental unit (chorion, amnion, placenta) of preeclamptic women are conflicting, with evidence for decreases, increases and no alteration (Brar et al., 1987; Singh et al., 2004; Kalenga et al., 1996; Poranen et al., 2009; Herse et al., 2007). The rise in ET-1 in preeclampsia (Verdonk et al., 2015), given its stimulatory effect on prorenin release in decidual cells (Chao et al., 1993), might support local prorenin upregulation. Nevertheless, in view of the normal circulating prorenin levels in preeclamptic women, prorenin upregulation, if occurring at all in either ovaries or the uteroplacental unit, is most likely modest. Herse observed decidual AT₁ receptor upregulation in preeclamptic women, and no change in decidual and placental renin, angiotensinogen or ACE, nor AT₁ receptor upregulation in the placenta (Herse et al., 2007). From these gene expression studies, it is difficult to conclusively state that there is selective RAAS upregulation at one or more sites in the uteroplacental unit.

In 1996, a mouse model was described with severe maternal hypotension during pregnancy, when mating transgenic females expressing human angiotensinogen with males expressing human renin (Takimoto et al., 1996). Here it is important to note that human renin does not react with mouse angiotensinogen (and vice versa), so that the single transgenic mice did not have a hypertensive phenotype. Interestingly, pregnancy-associated hypertension did not occur when crossing females expressing human renin with males expressing human angiotensinogen. The authors concluded that the placenta releases renin but not angiotensinogen into the circulation. Indeed, human renin could be demonstrated in maternal plasma at levels of 2.7 ng/mL, i.e., around 1000 times the normal renin level in humans (Campbell et al., 2009). Importantly, human prorenin levels in these mice were 57 ng/mL, which is also around 3 orders of magnitude above its normal levels in humans (and 100 times above the prorenin levels in pregnant women). Thus, in full agreement with the observations in humans, the placental release largely concerned prorenin. Furthermore, given that the human renin levels represented only a small fraction of the total human renin levels, it is likely that this in reality was prorenin in the open, active
conformation. The fact that there was no placental angiotensinogen release suggests that either angiotensinogen, unlike (pro)renin, cannot be released from its placental generation sites, or that there simply is no placental angiotensinogen production. The latter explanation is the most likely, since the placental angiotensinogen levels, unlike those of prorenin, are identical at different placental tissue sites (chorion leave, amnion, chorion plate and chorion fondrosus) (Lenz et al., 1989). This argues against a specific production site. Moreover, placental angiotensin is washed away during perfusion with buffer (Lenz et al., 1991). The fact that the follicular/ amniotic fluid levels resemble those in plasma suggests that also in the ovaries, angiotensinogen is derived from maternal blood (Glorioso et al., 1986; Paulson et al., 1989).

The double transgenic approach (human angiotensinogen females x human renin males) also yielded hypertension, proteinuria and growth restriction in pregnant rats, and this model is therefore suggested to be representative for preeclampsia. These rats displayed a PRA that was roughly 100 times the normal PRA in pregnant women (Verdonk et al., 2000), while their angiotensinogen levels were in the normal pregnancy range. Human prorenin levels were not determined in this model. But given that normally the placental contribution to plasma prorenin in pregnancy is <5% (Lenz et al., 1991), and assuming that the rise in PRA largely reflects the activity of open prorenin, it can be estimated that the placental release of human prorenin in these transgenic rodents must have been phenomenally high, possibly >10,000 times normal. When combined with human angiotensinogen, it is not surprising that this results in severe hypertension. Haase recently reported that human angiotensinogen siRNA targeted to the maternal liver suppressed the phenotype (Haase et al., 2020), raising the possibility that targeting the maternal RAAS may be beneficial in preeclampsia. However, whether this model truly mimics preeclampsia remains doubtful, since in reality preeclamptic women display significantly suppressed PRA levels. If the proteinuria and growth restriction in this animal model are due to the elevated PRA, this model may turn out to be less representative for the human situation. Nevertheless, these transgenic studies elegantly support the release of prorenin from the uteroplacental unit into blood, and prove that such release, if excessive, disturbs the normal maternal hemodynamic adaptation to pregnancy.

6. Prorenin and (patho)physiology of pregnancy course and outcomes

Most of the adverse pregnancy outcomes are likely to originate in the first trimester of pregnancy (Steegers-Theunissen et al., 2013). Insufficient hemodynamic adaptation preconception and during early pregnancy may also underlie fetal growth restriction (FGR) (Dudevot et al., 1995; Vasapollo et al., 2004; Salas et al., 2006; De Paco et al., 2008). To what degree this concerns suppressed circulating RAAS activation (like in preeclampsia) is unknown, although an impaired plasma volume expansion in the third trimester and low birthweight have been linked to low PRA and circulating aldosterone levels in late pregnancy (Salas and Rosso, 1998; Salas et al., 2006). Moreover, first trimester plasma angiotensinogen levels correlated positively with birth weight (Al Radi et al., 2005). Since low birth weight is a substantial determinant of a child’s health and a major risk factor for several noncommunicable diseases (Barker, 2007), these data indicate that dysregulated circulating RAAS activation in early pregnancy may also affect health later in life.

Low follicular/amniotic fluid prorenin levels might reduce local RAAS activity, thus diminishing the growth-stimulating and angiogenic effects of Ang II. A downregulation of placental AT1 receptors, as observed in FGR pregnancies (Knock et al., 1994; Li et al., 1998), would have a similar effect. Pregnancies achieved through IVF treatment are characterized by more frequent early and late vascular-related pregnancy complications. The risk factors for these complications are identical to those for women who conceive naturally and develop pregnancy complications, and include high maternal age, a high body mass index, chronic hypertension and diabetes mellitus (Bartsch et al., 2016). These risk factors are characterized by RAAS alterations and oxidative stress. For instance, diabetes mellitus, like pregnancy, associates with high prorenin levels (Bryer-Ash et al., 1983; Franken et al., 1990). Interestingly, pregnant women with diabetes mellitus who additionally develop preeclampsia displayed the highest prorenin levels (Ringholm et al., 2011). Oxidative stress impacts placental health during the critical hypoxic state (Jau-niaux et al., 2006; Burton et al., 2003) This may affect local renin regulation via epigenetic pathways (Wang et al., 2013).

7. Conclusions and future directions

Prorenin is among the factors released by the corpus luteum that determine maternal hemodynamic adaptation in early gestation. Animal data suggest that prorenin release by the placenta, if excessive, leads to hypertension, proteinuria and growth restriction. There is no evidence for conversion of this ovarian/placental prorenin to renin, and normally, at most a very small fraction of prorenin displays Ang I-generating activity without prosegment removal. This implies that only under conditions where prorenin release is far beyond normal (like in transgenic animals) such prorenin rises would substantially upregulate Ang II generation in the circulation. In humans this might also be the case in chorionic fluid, with its prorenin levels that are >1000-fold those in blood, and possibly in the immediate surrounding of cells that synthesize prorenin in the decidua and placenta. The angiotensinogen that is needed to allow local prorenin activity is of maternal origin, implying that it must be capable of passing the placental barrier. Angiotensinogen siRNA targeted to the maternal liver may thus help to prevent excessive RAAS activation, both in the mother and fetus. However, the pregnancy complication preeclampsia is characterized by low RAAS activity, and this may also be true for FGR. A wide range of local effects of Ang II in the ovary and uteroplacental unit has been described, ranging from oocyte maturation and decidualization to angiogenesis and regional blood flow modification. A remaining question is whether prorenin exerts effects beyond Ang II. Here its interaction with the (pro)renin receptor is of interest, although even the prorenin rises in pregnancy appear to be too limited to match the nanomolar affinity of this receptor. It has been argued that prorenin is a direct vasodilator, but the underlying mechanism remains unknown. A novel prorenin receptor is megalin, a transporter protein which is also abundantly present in the placenta. Its relationship with prorenin in the placenta remains to be determined. Future studies correlating prorenin levels with utero (placental) outcome and oxidative stress parameters could help to further determine the function of this prohormone. Careful linking of prorenin to other corpus luteum factors, corpus luteum number and IVF protocol will yield insight into its regulation and release. Here both relaxin and ET-1 are of great interest as prorenin modifiers. Low or absent relaxin levels (as occurring in women without a corpus luteum) promote preeclampsia, while ET-1 is upregulated in this condition. Since both relaxin and ET-1 upregulate prorenin, a unifying hypothesis might be that prorenin levels need to be in a specific range to allow optimal Ang II formation, with for instance too low levels resulting in insufficient AT1 receptor stimulation (required for corpus luteum formation and decidualization), and too high levels leading to deleterious AT2 receptor stimulation (inducing atresia).

Acknowledgements

The authors wish to thank Sabrina Gunput from the Erasmus MC Medical Library for her expertise and assistance in conducting the literature search in several databases.

Abbreviations

ACE angiotensin-converting enzyme
Ang angiotensin
AT<sub>1</sub> Ang II type 1
AT<sub>2</sub> Ang II type 2
cAMP cyclic adenosine monophosphate
eNOS endothelial NO synthase
ET-1 endothelin-1
FGFR fetal growth restriction
GFR glomerular filtration rate
hCG human chorionic gonadotropin
IVF in-vitro fertilization
LH luteinizing hormone
NO nitric oxide
PKC protein kinase C
PRA plasma renin activity
RAAS renin-angiotensin-aldosterone system
RNA ribonucleic acid
TNF tumor necrosis factor

Funding
Department of Obstetrics and Gynecology of the Erasmus Medical Center, Rotterdam, The Netherlands. This research did not receive any specific grant from funding agencies in the public, commercial or not-for-profit sectors.

Declaration of competing interest
The authors have no conflict of interest to disclose.

References
Alvarenga R.E. Wiegel et al.


Jikihara, H., Poisner, A.M., Handwerger, S., 1995. Tumor necrosis factor-
Lu, X., Meima, M.E., Nelson, J.K., et al., 2016. Identification of the (pro)renin receptor as
Landau, R.L., Lugibihl, K., 1958. Inhibition of the sodium-retaining influence of
Kalenga, M.K., Thomas, K., de Gasparo, M., et al., 1996. Determination of renin,
Griswold, R.E. Wiegel et al.
Update 12, 747–755.
Jikihara, H., Poisner, A.M., Handwerger, S., 1995. Tumor necrosis factor-α and
Salas, S.P., Marshall, G., Gutierrez, B.L., et al., 2006. Time course of maternal plasma volume and hormonal changes in women with preeclampsia or fetal growth restriction. Hypertension 47, 203–208.


